title: Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology.
authors.affiliation: Winthrop University Hospital, Mineola, MN, USA.
authors.forename: Luz
authors.initials: L
authors.lastname: Fonacier
authors.forename: Jonathan
authors.initials: J
authors.lastname: Spergel
authors.forename: Ernest N
authors.initials: EN
authors.lastname: Charlesworth
authors.forename: David
authors.initials: D
authors.lastname: Weldon
authors.forename: Vincent
authors.initials: V
authors.lastname: Beltrani
authors.forename: Jan
authors.initials: J
authors.lastname: Bernhisel-Broadbent
authors.forename: Mark
authors.initials: M
authors.lastname: Boguniewicz
authors.forename: Donald Y M
authors.initials: DY
authors.lastname: Leung
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000818:Animals; D065095:Calcineurin Inhibitors; D002648:Child; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D008223:Lymphoma / Q000139:chemically induced; D051379:Mice; D009369:Neoplasms / Q000453:epidemiology; D009374:Neoplasms, Experimental / Q000139:chemically induced; D011358:Product Surveillance, Postmarketing; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use*
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; C117268:pimecrolimus; D016559:Tacrolimus